Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Urinary Bladder Neoplasms 3Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × valrubicin × Clear all
NCT00003129 2023-06-22

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
75 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT01606345 2016-04-22

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
4 enrolled
Genitourinary

Carcinoma, Transitional Cell, Neoplasms

NCT01316874 2015-06-12

Bladder Cancer

Endo Pharmaceuticals

Phase 2/3 Completed
90 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT00003759 2013-01-31

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡